Real-world platinum selection in immune checkpoint inhibitor-based therapy for recurrent or metastatic head and neck cancer: an exploratory multi-institutional retrospective study.

Despite the inclusion of patients with an ECOG PS 2, the observed median PFS was consistent with that reported in the KEYNOTE-048 trial, and the median OS showed a trend toward improvement 12 , 13 .

also in 53,322 other papers